Evidence map›Paper›PMID 35278143›Full record

ArticleCellular and molecular life sciences : CMLS2022

Subcellular progression of mesenchymal transition identified by two discrete synchronous cell lines derived from the same glioblastoma.

Sojin Kim, Soo-Ji Park, Tamrin Chowdhury, Jeong-Im Hong, Jinhee Ahn, Tae Yeong Jeong, Hyeon Jong Yu, Young-Kyoung Shin, Ja-Lok Ku, Jong Bae Park and 4 more

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sojin Kim *Department of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
Soo-Ji Park *Department of Physiology, Korea University College of Medicine, Seoul, 02841, Republic of Korea.
Tamrin Chowdhury *Department of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
Jeong-Im HongDepartment of Physiology, Korea University College of Medicine, Seoul, 02841, Republic of Korea.
Jinhee AhnDepartment of Physiology, Korea University College of Medicine, Seoul, 02841, Republic of Korea.
Tae Yeong JeongDepartment of Physiology, Korea University College of Medicine, Seoul, 02841, Republic of Korea.
Hyeon Jong YuDepartment of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
Young-Kyoung ShinKorean Cell Line Bank, Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
Ja-Lok KuKorean Cell Line Bank, Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
Jong Bae ParkDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, 10408, Republic of Korea.
Junho K HurDepartment of Genetics, College of Medicine, Hanyang University, Seoul, 04763, Republic of Korea.
Hwajin LeeBiomedical Knowledge Engineering Laboratory, Seoul National University, Seoul, 08826, Republic of Korea. hwajin2k@gmail.com.
Kyoungmi KimDepartment of Physiology, Korea University College of Medicine, Seoul, 02841, Republic of Korea. kim0912@korea.ac.kr.ORCID http://orcid.org/0000-0003-0941-806X
Chul-Kee ParkDepartment of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea. nsckpark@snu.ac.kr.

Funding

Korea Health Industry Development Institute HI21C0239National Research Foundation of Korea 2018M3A9H3021707National Research Foundation of Korea 2019R1A2C2087198National Research Foundation of Korea 2020M3A9D5A01082439
6 · The paper itself

Abstract

Glioblastomas (GBM) exhibit intratumoral heterogeneity of various oncogenic evolutional processes. We have successfully isolated and established two distinct cancer cell lines with different morphological and biological characteristics that were derived from the same tissue sample of a GBM. When we compared their genomic and transcriptomic characteristics, each cell line harbored distinct mutation clusters while sharing core driver mutations. Transcriptomic analysis revealed that one cell line was undergoing a mesenchymal transition process, unlike the other cell line. Furthermore, we could identify four tumor samples containing our cell line-like clusters from the publicly available single-cell RNA-seq data, and in a set of paired longitudinal GBM samples, we could confirm three pairs where the recurrent sample was enriched in the genes specific to our cell line undergoing mesenchymal transition. The present study provides direct evidence and a valuable source for investigating the ongoing process of subcellular mesenchymal transition in GBM, which has prognostic and therapeutic implications.

Indexed as

AnimalsBrain NeoplasmsCell Line, TumorDisease ProgressionDNA Copy Number VariationsEpithelial-Mesenchymal TransitionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGlioblastomaHumansMiceMice, NudeSingle-Cell AnalysisTransplantation, HeterologousGlioblastomaIntratumoral heterogeneityMesenchymal transitionSynchronous cell lines

Identifiers

PMID35278143
PMCPMC8918182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.